ZGNX - Zogenix, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD

Zogenix, Inc.

5858 Horton Street
Suite 455
Emeryville, CA 94608
United States

IndustryDrug Manufacturers - Major
Full Time Employees67

Key Executives

Dr. Stephen J. Farr Ph.D.Co-Founder, CEO, Pres & Director677.89kN/A58
Mr. Roger L. HawleyCo-Founder & DirectorN/AN/A64
Dr. Bradley S. Galer M.D.Exec. VP & Chief Medical Officer510.23kN/A55
Dr. Gail M. Farfel Ph.D.Exec. VP & Chief Devel. Officer477.06kN/A53
Ms. Ann D. RhoadsConsultant498.27kN/A52
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. The company's lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. It also develops Relday, an injectable formulation of risperidone to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.

Corporate Governance

Zogenix, Inc.’s ISS Governance QualityScore as of February 1, 2018 is 7. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.